Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
23 words
Use of a dsRNA for the manufacture of a medicament for rendering or maintaining a virus-infected animal susceptible to antiviral or immunological therapy.
Claim 2
Dependent Claim
23 words
Use of a dsRNA for the manufacture of a medicament for rendering or maintaining a virus-infected animal susceptible to antiviral or immunological therapy.
Claim 3
Independent Claim
36 words
A method of treating virus-infected animal cells in vitro to reduce or prevent viral escape comprising the step of treating the said cells with an amount of a dsRNA effective to reduce or prevent viral escape.
Claim 4
Independent Claim
36 words
A method of treating virus-infected animal cells in vitro to reduce or prevent viral escape comprising the step of treating the said cells with an amount of a dsRNA effective to reduce or prevent viral escape.
Claim 5
Dependent Claim
41 words
Use of a dsRNA for the manufacture of a medicament for the treatment of an animal susceptible to viral infection by protecting the animal against viral-induced pathology secondary to antigenic drift as evidenced by molecular rearrangement of the viral particle structure.
Claim 6
Dependent Claim
41 words
Use of a dsRNA for the manufacture of a medicament for the treatment of an animal susceptible to viral infection by protecting the animal against viral-induced pathology secondary to antigenic drift as evidenced by molecular rearrangement of the viral particle structure.
Claim 7
Dependent Claim
36 words
Use of a dsRNA for the manufacture of a medicament for the treatment of animals by fixing and isolating the molecular arrangement of a viral particle structure while maintaining the particle's molecular arrangement within predetermined limits.
Claim 8
Dependent Claim
36 words
Use of a dsRNA for the manufacture of a medicament for the treatment of animals by fixing and isolating the molecular arrangement of a viral particle structure while maintaining the particle's molecular arrangement within predetermined limits.
Claim 9
Dependent Claim
25 words
The use of any one of claims 1, 3 and 4, or the method of claim 2 in which the dsRNA is a mismatched dsRNA.
Claim 10
Dependent Claim
44 words
The use of any of claims 1, 3, 4 and 5 or the method of claim 2 in which the mismatched dsRNA is a complex of a polyinosinate and a polycytidylate containing from 1 in 5 to 1 in 30 uracil or guanidine bases.
Claim 11
Dependent Claim
30 words
The use of any one of claims 1, 3, 4, 5 and 6 or the method of claim 2 in which the mismatched dsRNA is rI n .r(C₂₉,G) n .
Claim 12
Dependent Claim
31 words
The use of any one of claims 1, 3, 4, 5, 6 and 7 or the method of claim 2 in which the mismatched dsRNA is rI n .r(C₁₁₋₁₄,U) n .
Claim 13
Dependent Claim
45 words
The use of any one of claims 1, 3, 4, 5, 6 7 and 8 of the method of claim 2 in which the dsRNA contains regions of bond breakage and the dsRNA exhibits the favourable therapeutic ratio property of rI n .r(C₁₁₋₁₄,U) n .